Application No: NA_00068294
Principal Investigator: Daniel Harrison
For more information please contact Julie Fiol at 410-955-8704
This research is being conducted to determine if natalizumab is effective in slowing disability progression in multiple sclerosis patients with secondary progression. Natalizumab is a once monthly intravenous infusion that is currently FDA-approved for use in relapsing remitting MS.
Participants must be between the ages of 18 and 58 and have a diagnosis of secondary progressive MS with evidence of disability progression for more than 2 years independent of relapses. Participants will be randomized to receive once-monthly infusions of natalizumab or placebo.